The Lancet Oncology in conversation with

Release Date

All Episodes

Iberdomide, daratumumab, and dexamethasone in relapsed or refractory multiple myeloma with Professor Lonial

Iberdomide, daratumumab, and dexamethasone as a treatment option for patients with relapsed or refractory multiple myeloma. Click here the full article: S1470-2045(26)00450-X

. 6min 41sec

Accelerating equitable cancer genomics and precision oncology with Raffaella Casolino and Mark Lawler

In this special episode, Dr Cheryl Lai, Acting Deputy Editor at The Lancet Oncology, is joined by Dr Raffaella Casolino (University of Glasgow, UK; International Cancer Genome Consortium - Accelerating Research in Genomic Oncology) and Professor Mark Lawler (Queen's University Be ... Afficher plus

. 15min 38sec

Tumour-infiltrating lymphocytes in breast cancer with Professor Sherene Loi

Professor Sherene Loi and the International Immuno-Oncology Biomarker Working Group on tumour-infiltrating lymphocytes as breast cancer biomarkers. Two Articles cover AI and digital pathology scoring methods and a Review examines integrating TILs into radiation oncology trials an ... Afficher plus

. 17min 49sec

5-year quality of life study of the SUPREMO trial examining chest wall radiotherapy in patients with intermediate-risk breast cancer with Professor Galina Velikova

5-year quality of life (QOL) substudy of the SUPREMO trial examining the effects of chest wall radiotherapy versus no chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. The data will put patients in a better position to make an informed tre ... Afficher plus

. 11min 48sec